Hoban D J, Zhanel G G, Karlowsky J A
Department of Medical Microbiology, University of Manitoba, Winnipeg, Manitoba, Canada.
Antimicrob Agents Chemother. 1999 Jun;43(6):1463-4. doi: 10.1128/AAC.43.6.1463.
Fluconazole-resistant Candida albicans and intrinsically fluconazole-resistant Candida species have been reported as bloodstream isolates. However, an association between the isolation of fluconazole-resistant Candida from the bloodstream and patient risk factors for fungemia has not been established. The purpose of this study was to determine the prevalence of fluconazole resistance in bloodstream isolates of Candida species and Cryptococcus neoformans collected from patients with neutropenia, one of the most important risk factors for fungemia. MICs of voriconazole, fluconazole, itraconazole, ketoconazole, amphotericin B, and flucytosine were determined by the National Committee for Clinical Laboratory Standards M27-A method (1997). Voriconazole, on a per-weight basis, was the most active azole tested. Fluconazole resistance (MIC >/= 64 microg/ml) was not identified in any of the C. albicans (n = 513), Candida parapsilosis (n = 78), Candida tropicalis (n = 62), or C. neoformans (n = 38) isolates tested.
已有报道称耐氟康唑的白色念珠菌和天然耐氟康唑的念珠菌属为血流感染分离株。然而,从血流中分离出耐氟康唑念珠菌与真菌血症患者危险因素之间的关联尚未确立。本研究的目的是确定从患有中性粒细胞减少症(真菌血症最重要的危险因素之一)的患者中分离出的念珠菌属和新生隐球菌血流感染分离株中氟康唑耐药的患病率。伏立康唑、氟康唑、伊曲康唑、酮康唑、两性霉素B和氟胞嘧啶的最低抑菌浓度(MIC)通过美国国家临床实验室标准委员会M27 - A方法(1997年)测定。按单位重量计算,伏立康唑是所测试的活性最高的唑类药物。在所测试的任何白色念珠菌(n = 513)、近平滑念珠菌(n = 78)、热带念珠菌(n = 62)或新生隐球菌(n = 38)分离株中均未发现氟康唑耐药(MIC≥64μg/ml)。